Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
NCT ID: NCT03030105
Last Updated: 2018-10-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
38 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-01-31
Study Completion Date
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
NCT02840279
Alzheimer's Disease
COMPLETED
PHASE1
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
NCT01181310
Dementia
COMPLETED
PHASE1
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
NCT02648672
Alzheimer's Disease
COMPLETED
PHASE1
TAK-071 Scopolamine-Induced Cognitive Impairment Study
NCT02918266
Healthy Volunteers
TERMINATED
PHASE1
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
NCT01044342
Cognition
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 38 subjects will be enrolled into the study. The study duration will be up to 12 weeks with 6 weeks of single-dose Treatment Visits. The study will consist of a Screening Visit (up to 28 days prior to first study drug administration), six inpatient Treatment Visits (Periods 1 through 6), and a Follow-Up/Early Termination Visit (7-10 days after the last dose of study medication). An additional study visit may be necessary to complete the required cognitive test familiarization if not completed during the Screening Visit. Each Treatment Visit will occur approximately one week apart, allowing a 6 to 8 day washout period.
Subjects will be randomized to 1 of 6 treatment sequences based on a computer-generated randomization schedule. Subjects will receive all 6 treatments as specified by the treatment sequence according to a 6 × 6 Williams Latin square design. The following treatments will be administered:
A. Scopolamine placebo + BPN14770 placebo + donepezil placebo
B. Scopolamine 0.5 mg + BPN14770 placebo + donepezil placebo
C. Scopolamine 0.5 mg + BPN14770 10 mg + donepezil placebo
D. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil placebo
E. Scopolamine 0.5 mg + donepezil 10 mg +BPN14770 placebo
F. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil 10 mg
During each of the Treatment Visits (Periods 1 through 6), subjects will be admitted to the Clinical Research Unit (CRU) the day prior to each study drug administration (Day -1) and discharged the day after study drug administration (Day 2). On the morning of study drug administration (Day 1), subjects will be given study drug (BPN14770, donepezil, or placebo) with 240mL of room temperature water 2 hours prior to the scopolamine or scopolamine placebo sc injection. The timing for study drug administration will be referred to as t-2 (Hour -2). Breakfast should be available approximately 30 minutes following the morning drug administration. Two hours after study drug administration, the scopolamine or scopolamine placebo sc injection will be administered. The time at which the scopolamine or scopolamine placebo sc injection is administered will be referred to as t0 (Hour 0).
Cognitive testing will be performed 30 minutes prior to treatment with scopolamine injection and at hours 1, 2, 3, 4, and 6 post-scopolamine injection.
PK samples will be collected during the treatment period to confirm study drug is present.
Safety assessments throughout the study will include physical exams, ECGs, vital signs, chemistry, hematology, and urinalysis.
Subjects will be randomized to 1 of 6 treatment sequences based on a computer-generated randomization schedule. Subjects will receive all 6 treatments as specified by the treatment sequence according to a 6 × 6 Williams Latin square design. The following treatments will be administered:
A. Scopolamine placebo + BPN14770 placebo + donepezil placebo
B. Scopolamine 0.5 mg + BPN14770 placebo + donepezil placebo
C. Scopolamine 0.5 mg + BPN14770 10 mg + donepezil placebo
D. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil placebo
E. Scopolamine 0.5 mg + donepezil 10 mg +BPN14770 placebo
F. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil 10 mg
During each of the Treatment Visits (Periods 1 through 6), subjects will be admitted to the Clinical Research Unit (CRU) the day prior to each study drug administration (Day -1) and discharged the day after study drug administration (Day 2). On the morning of study drug administration (Day 1), subjects will be given study drug (BPN14770, donepezil, or placebo) with 240mL of room temperature water 2 hours prior to the scopolamine or scopolamine placebo sc injection. The timing for study drug administration will be referred to as t-2 (Hour -2). Breakfast should be available approximately 30 minutes following the morning drug administration. Two hours after study drug administration, the scopolamine or scopolamine placebo sc injection will be administered. The time at which the scopolamine or scopolamine placebo sc injection is administered will be referred to as t0 (Hour 0).
Cognitive testing will be performed 30 minutes prior to treatment with scopolamine injection and at hours 1, 2, 3, 4, and 6 post-scopolamine injection.
PK samples will be collected during the treatment period to confirm study drug is present.
Safety assessments throughout the study will include physical exams, ECGs, vital signs, chemistry, hematology, and urinalysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A) P:P:P
Scopolamine placebo : BPN14770 placebo : Donepezil placebo
Group Type
PLACEBO_COMPARATOR
BPN14770 placebo
Intervention Type
DRUG
placebo
Donepezil placebo
Intervention Type
DRUG
placebo
Scopolamine placebo
Intervention Type
DRUG
placebo
B) S:P:P
Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
Group Type
PLACEBO_COMPARATOR
BPN14770 placebo
Intervention Type
DRUG
placebo
Donepezil placebo
Intervention Type
DRUG
placebo
Scopolamine 0.6 MG/ML
Intervention Type
DRUG
cognition impairment
C) S:B:P
Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
Group Type
EXPERIMENTAL
BPN14770
Intervention Type
DRUG
investigational drug
Donepezil placebo
Intervention Type
DRUG
placebo
Scopolamine 0.6 MG/ML
Intervention Type
DRUG
cognition impairment
D) S:B:P
Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
Group Type
EXPERIMENTAL
BPN14770
Intervention Type
DRUG
investigational drug
Donepezil placebo
Intervention Type
DRUG
placebo
Scopolamine 0.6 MG/ML
Intervention Type
DRUG
cognition impairment
E) S:P:D
Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
Group Type
ACTIVE_COMPARATOR
BPN14770 placebo
Intervention Type
DRUG
placebo
Donepezil
Intervention Type
DRUG
comparator
Scopolamine 0.6 MG/ML
Intervention Type
DRUG
cognition impairment
F) S:B:D
Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
Group Type
EXPERIMENTAL
BPN14770
Intervention Type
DRUG
investigational drug
Donepezil
Intervention Type
DRUG
comparator
Scopolamine 0.6 MG/ML
Intervention Type
DRUG
cognition impairment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BPN14770
investigational drug
Intervention Type
DRUG
BPN14770 placebo
placebo
Intervention Type
DRUG
Donepezil
comparator
Intervention Type
DRUG
Donepezil placebo
placebo
Intervention Type
DRUG
Scopolamine 0.6 MG/ML
cognition impairment
Intervention Type
DRUG
Scopolamine placebo
placebo
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Aricept
Aricept placebo
Hyoscine s.c.
Hyoscine s.c. placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Healthy males or females between the ages of 18 to 55 years at Screening.
2. Body mass index between 18 kg/m2 to 33 kg/m2, inclusive, and body weight of \>50 kg (110 pounds).
3. Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), at least two years post-menopausal, or willing to either (1) utilize hormonal contraception plus use one barrier method or (2) use two barrier methods of contraception from initial screening until one month after taking the final dose. Barrier methods of contraception include diaphragm, cervical cap, male condom, female condom, and spermicidal foam and sponges. An intrauterine device (IUD) is also considered a barrier method of contraception in this study; if the subject is using an IUD, she will need to use an additional barrier method of contraception. Menopausal status will be verified by testing for follicle stimulating hormone (FSH ≥25 mIU/mL) at Screening. In addition, all females must have a negative blood test for pregnancy within 28 days during the Screening period and negative urine test for pregnancy on Day-1 of each Treatment Visit regardless of childbearing potential.
4. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control).
5. Able to understand the study procedures, voluntarily consent to participate in this study, and provide written informed consent prior to start of any study-specific procedures.
6. Willing and able to remain in the study unit for the required periods and return for each treatment of the six treatment periods, including the outpatient visits.
2. Body mass index between 18 kg/m2 to 33 kg/m2, inclusive, and body weight of \>50 kg (110 pounds).
3. Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), at least two years post-menopausal, or willing to either (1) utilize hormonal contraception plus use one barrier method or (2) use two barrier methods of contraception from initial screening until one month after taking the final dose. Barrier methods of contraception include diaphragm, cervical cap, male condom, female condom, and spermicidal foam and sponges. An intrauterine device (IUD) is also considered a barrier method of contraception in this study; if the subject is using an IUD, she will need to use an additional barrier method of contraception. Menopausal status will be verified by testing for follicle stimulating hormone (FSH ≥25 mIU/mL) at Screening. In addition, all females must have a negative blood test for pregnancy within 28 days during the Screening period and negative urine test for pregnancy on Day-1 of each Treatment Visit regardless of childbearing potential.
4. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control).
5. Able to understand the study procedures, voluntarily consent to participate in this study, and provide written informed consent prior to start of any study-specific procedures.
6. Willing and able to remain in the study unit for the required periods and return for each treatment of the six treatment periods, including the outpatient visits.
Exclusion Criteria
1. Clinically significant abnormality, in the Investigator's judgement, in Screening hematology, chemistry, or urinalysis tests, or from medical history, social history, vital sign, or physical examination
2. Active liver disease or positive serology results for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
3. Abnormal liver function test at the Screening Visit (aspartate aminotransferase or alanine aminotransferase \>2 × the upper limit of normal \[ULN\]; total bilirubin \>1.5 × ULN; or alkaline phosphatase \>2 × ULN based on appropriate age and gender normal values).
4. Current or past history of angle closure glaucoma, or diagnosis of angle closure glaucoma.
5. Marked hypotension (systolic blood pressure \[BP\] ˂90 mmHg or diastolic BP ˂50 mmHg) or hypertension (systolic BP ˃150 mmHg or diastolic BP ˃100 mmHg) based on sitting values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
6. Marked bradycardia (heart rate ˂45 beats per minute \[bpm\]) or tachycardia (heart rate ˃110 bpm) based on supine ECG values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
7. Current or past history of significant (in the Investigator's judgement) cardiovascular, cerebrovascular, pulmonary, renal, or liver disease. Stable, well-controlled hypertension and hyperlipidemias are allowed.
8. Clinically important or significant conduction abnormalities on single ECG or evidence or history of long QT syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once at Screening.
9. Current or past history of gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
10. Active acute or chronic infectious diseases.
11. Unable to discontinue medications including anticholinergic agents, psychotropic drugs, sedative antihistamines, or other centrally active medications \[e.g., CNS- penetrant beta blockers\], and moderate to strong inhibitors or inducers of CYP3A4, CYP2D6, or other cytochromes) 14 days prior to the first dose of study drug (Period 1, Day 1) and during the study (Follow-Up). Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering drugs are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.
12. Unable to discontinue and abstain from over-the-counter, herbal preparations, dietary supplements, nutraceuticals, vitamins and minerals at least 7 days prior to the first dose of study drug and during the study. The one exception to this rule is acetaminophen, which may be taken for minor ailments at doses up to 1000 mg per day.
13. Any history of alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).
14. Any use of alcohol, grapefruit, marijuana, or other psychotropic agent within 12 hours of admission into the CRU.
15. Active smokers or tobacco users (e.g., chew and snuff) who are unable to discontinue tobacco use or nicotine-containing products (including e-cigarettes) at least 4 weeks prior to Screening and to refrain from using during the study.
16. Inability or unwillingness to comply with the protocol or likely inability to complete the study.
17. Participation in other clinical studies involving investigational drug within the previous 30 days prior to the Screening Visit.
18. Donation of blood within the prior 4 weeks, or blood products within the prior 2 weeks, prior to first study drug administration.
19. Positive result for drugs of abuse, alcohol, or cotinine at Screening, or a positive drug or alcohol (breath) result upon admission to CRU.
20. History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema. This includes known hypersensitivity to donepezil hydrochloride, scopolamine, or belladonna, alkaloids.
21. Inability or unwillingness to perform the Cogstate cognitive function tests.
22. A suicidal ideation intensity score of 2 or higher per screening Columbia Suicide Severity Rating Scale (C-SSRS) assessment and/or any suicidal behavior within the past 28 days.
2. Active liver disease or positive serology results for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
3. Abnormal liver function test at the Screening Visit (aspartate aminotransferase or alanine aminotransferase \>2 × the upper limit of normal \[ULN\]; total bilirubin \>1.5 × ULN; or alkaline phosphatase \>2 × ULN based on appropriate age and gender normal values).
4. Current or past history of angle closure glaucoma, or diagnosis of angle closure glaucoma.
5. Marked hypotension (systolic blood pressure \[BP\] ˂90 mmHg or diastolic BP ˂50 mmHg) or hypertension (systolic BP ˃150 mmHg or diastolic BP ˃100 mmHg) based on sitting values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
6. Marked bradycardia (heart rate ˂45 beats per minute \[bpm\]) or tachycardia (heart rate ˃110 bpm) based on supine ECG values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
7. Current or past history of significant (in the Investigator's judgement) cardiovascular, cerebrovascular, pulmonary, renal, or liver disease. Stable, well-controlled hypertension and hyperlipidemias are allowed.
8. Clinically important or significant conduction abnormalities on single ECG or evidence or history of long QT syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once at Screening.
9. Current or past history of gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
10. Active acute or chronic infectious diseases.
11. Unable to discontinue medications including anticholinergic agents, psychotropic drugs, sedative antihistamines, or other centrally active medications \[e.g., CNS- penetrant beta blockers\], and moderate to strong inhibitors or inducers of CYP3A4, CYP2D6, or other cytochromes) 14 days prior to the first dose of study drug (Period 1, Day 1) and during the study (Follow-Up). Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering drugs are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.
12. Unable to discontinue and abstain from over-the-counter, herbal preparations, dietary supplements, nutraceuticals, vitamins and minerals at least 7 days prior to the first dose of study drug and during the study. The one exception to this rule is acetaminophen, which may be taken for minor ailments at doses up to 1000 mg per day.
13. Any history of alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).
14. Any use of alcohol, grapefruit, marijuana, or other psychotropic agent within 12 hours of admission into the CRU.
15. Active smokers or tobacco users (e.g., chew and snuff) who are unable to discontinue tobacco use or nicotine-containing products (including e-cigarettes) at least 4 weeks prior to Screening and to refrain from using during the study.
16. Inability or unwillingness to comply with the protocol or likely inability to complete the study.
17. Participation in other clinical studies involving investigational drug within the previous 30 days prior to the Screening Visit.
18. Donation of blood within the prior 4 weeks, or blood products within the prior 2 weeks, prior to first study drug administration.
19. Positive result for drugs of abuse, alcohol, or cotinine at Screening, or a positive drug or alcohol (breath) result upon admission to CRU.
20. History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema. This includes known hypersensitivity to donepezil hydrochloride, scopolamine, or belladonna, alkaloids.
21. Inability or unwillingness to perform the Cogstate cognitive function tests.
22. A suicidal ideation intensity score of 2 or higher per screening Columbia Suicide Severity Rating Scale (C-SSRS) assessment and/or any suicidal behavior within the past 28 days.
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tetra Discovery Partners
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cassandra Key, MD
Role: PRINCIPAL_INVESTIGATOR
ICON Early Phase Services, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICON Early Phase Services, LLC
Austin, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BPN14770-CNS-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
NCT02051335
COMPLETED
PHASE1
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
NCT01345864
TERMINATED
PHASE1
Scopolamine Challenge Study
NCT01213355
COMPLETED
PHASE1
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
NCT00710684
COMPLETED
PHASE2
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
NCT03817684
COMPLETED
PHASE2
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
NCT00708552
COMPLETED
PHASE2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT03131453
TERMINATED
PHASE2/PHASE3
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
NCT03114657
TERMINATED
PHASE3
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616
COMPLETED
PHASE2
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572
COMPLETED
PHASE2
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
NCT02255799
COMPLETED
PHASE3
Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers
NCT01461174
COMPLETED
PHASE1
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727
RECRUITING
PHASE1
A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
NCT03698695
COMPLETED
PHASE1
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
COMPLETED
PHASE1/PHASE2
SB-742457 And Donepezil In Alzheimer's Disease
NCT00348192
COMPLETED
PHASE2
Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
NCT00100334
COMPLETED
PHASE1/PHASE2
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
NCT05267535
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
NCT03906123
UNKNOWN
NA
Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients
NCT00706186
TERMINATED
PHASE4
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
NCT01039701
COMPLETED
PHASE2
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
NCT03757325
COMPLETED
PHASE1
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
NCT02079909
COMPLETED
PHASE2
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02337907
COMPLETED
PHASE2